Orexigen Therapeutics (OREX) : 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Orexigen Therapeutics (OREX). Zacks Investment Research suggests a Hold with a rank of 3. 1 analysts perceive the stock to be overvalued at the existing levels, hence their call is to Sell the stock.The median of all the 3 Wall Street Analysts endorse the stock as a Hold with a rating of 3.33.
Shares of Orexigen Therapeutics, Inc. rose by 1.64% in the last five trading days and 26.53% for the last 4 weeks. Orexigen Therapeutics, Inc. is up 0.93% in the last 3-month period. Year-to-Date the stock performance stands at -74.77%. Orexigen Therapeutics (NASDAQ:OREX): On Tuesdays trading session , Opening price of the stock was $4.46 with an intraday high of $4.4899. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.2944. However, the stock managed to close at $4.34, a loss of 1.59% for the day. On the previous day, the stock had closed at $4.41. The total traded volume of the day was 77,341 shares.
Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Companys product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Companys product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.